Palvella Therapeutics
PVLA
24 hedge funds and large institutions have $28.3M invested in Palvella Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.59% more ownership
Funds ownership: 0% → 0.59% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 29 → 24 (-5)
24% less capital invested
Capital invested by funds: $37.4M → $28.3M (-$9.14M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$1.3M |
| 2 |
Morgan Stanley
New York
|
+$167K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$40.7K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$38.7K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.15M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$383K |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$235K |
| 4 |
Renaissance Technologies
New York
|
-$79K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$63K |
PVLA Hedge Fund Activity: Q4 2016 in Review
24 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2016, worth a combined $28.3M — down 24% from $37.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PVLA and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was BVF Inc, adding an estimated $1.3M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $1.15M.
- 24 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2016, down from 29 in Q3 2016.
- Funds reported $28.3M of Palvella Therapeutics stock for Q4 2016, down 24% quarter-over-quarter.
- 3 funds opened new Palvella Therapeutics positions in Q4 2016 and 8 closed out, a net change of -5 holders.
- The largest Palvella Therapeutics buyer in Q4 2016 was BVF Inc, an estimated $1.3M added.
- The largest Palvella Therapeutics seller in Q4 2016 was Lombard Odier Asset Management (USA), an estimated $1.15M sold.
Based on aggregated 13F filings for Q4 2016.